Is augmentation therapy recommended for everyone with alpha-1 antitrypsin deficiency?
Augmentation therapy for people with alpha-1 antitrypsin deficiency (AATD) is not recommended for individuals with the MZ genotype (or other carrier genotypes), individuals with AATD-related lung disease who continue to smoke, individuals with AATD and emphysema or bronchiectasis who do not have airflow obstruction, for the treatment of AATD liver disease, or for those who have undergone liver transplantation.
Medical guidelines can be found at http://journal.copdfoundation.org/jcopdf/id/1115/The-Diagnosis-and-Management-of-Alpha-1-Antitrypsin-Deficiency-in-the-Adult
Alpha-1 Foundation. Treatment. Retrieved from https://www.alpha1.org/Newly-Diagnosed/Living-with-Alpha-1/Treatment.
Sandhaus RA, Turino G, Brantly ML, et al. Clinical Practice Guidelines: The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Journal of the COPD Foundation. Vol. 3, No. 3. 2016. Retrieved from https://journal.copdfoundation.org/Portals/0/JCOPDF/Files/Volume3-Issue3/JCOPDF-2015-0182-Sandhaus.pdf.